Mevim S.p.A. (BIT:MEV)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 13, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	2	2	5	1	2	4
Market Cap Growth	-67.07%	-67.07%	286.33%	-13.79%	-60.62%	-50.91%
Enterprise Value	2	2	4	3	2	4
Last Close Price	0.40	0.54	1.64	2.75	3.19	8.10
PS Ratio	0.32	0.28	0.91	0.28	0.53	2.61
PB Ratio	0.79	0.70	1.19	1.68	4.06	1.32
P/OCF Ratio	51.66	45.86	-	-	-	-
EV/Sales Ratio	0.39	0.32	0.82	0.63	0.58	2.92
Debt / Equity Ratio	0.23	0.23	0.10	3.00	6.58	0.37
Asset Turnover	0.71	0.71	0.69	0.68	0.29	0.11
Inventory Turnover	6.52	6.52	6.33	6.91	2.60	0.85
Quick Ratio	0.55	0.55	0.92	0.41	0.24	0.14
Current Ratio	0.79	0.79	1.28	1.04	0.40	0.42
Return on Equity (ROE)	-56.72%	-56.72%	-77.62%	-209.16%	-323.58%	-142.41%
Return on Assets (ROA)	-12.52%	-12.52%	-13.64%	-8.53%	-50.31%	-8.90%
Return on Capital (ROIC)	-27.38%	-27.38%	-28.36%	-20.26%	-144.78%	-21.53%
Earnings Yield	-100.26%	-112.95%	-38.63%	-92.00%	-352.29%	-184.22%

Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.